Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Pharm Chapter 30
Drug Therapy for Heart Failure
| Question | Answer |
|---|---|
| Condition that results in low cardiac output due to the heart's inability to pump sufficient blood to meet the metabolic demands of the body. | Heart failure |
| The result of abnormal electrical impulse conduction in the heart. | Cardiac dysrhythmias |
| Active amines, such as epinephrine, norepinephrine, and dopamine that have a "flight or fight" effect on the cardiovascular system. | Catecholamines |
| The increased sympathetic nervous system activity is ___________; increasing the patient's heart rate and constricting blood vessels. | Chronotropic |
| Enzyme produced in the kidneys in response to impaired blood flow and tissue perfussion. | Renin |
| A potent vasoconstrictor and may exert additional direct toxic effects on the heart. | Endothelin |
| Two of the natriuretic peptides, atrial or A type NP (ANP) and ___________ are most commonly associated with heart failure. | BNP |
| Results in a decrease in cardiac output related to an increase in left atrial and left ventricular end-diastolic pressures and congestion in the pulmonary circulation. | Left sided heart failure |
| Results from an accumulation of blood in the systemic venous system. | Right sided heart failure |
| Cardiac glycosides prototype | Digoxin |
| Digoxin improves symptoms and quality of life; it is considered a _________ line therapy. | Second |
| In a patient with an atrial fibrillation with heart failure, digoxin slows the rate of _____________________ (negative chronotropy). | Ventricular contraction |
| The margin between effectiveness and toxicity in the blood level of the medication. | Therapeutic index |
| Administration of a loading dose of digoxin to reach the therapeutic index. | Digitalization |
| Phosphodiesterase inhibitor prototype | Milrinone |
| Indicated intermediate and long term as bridge therapy in heart failure. | Milrinone |
| While receiving Milrinone, it is important to frequently monitor blood pressure, pulse, and ______________________ | Heart rhythm |
| Angiotensin Receptor - Neprilysin Inhibitors prototype | Sacubitril/valsartan |
| African Americans are at a higher risk of developing this with administration of sacubitril/valsartan. | Angioedema |
| Sinoatrial node modulators prototype | Ivabradine |
| One adverse effect of ivabradine is the intermittent enhanced brightness in a limited area of the visual field, halos, or multiple images, which is also called __________. | Phosphene |
| Angiotensin-Converting Enzyme Inhibitor prototype for heart failure. | Enalapril |
| Beta Adrenergic Blocking Agent prototype for heart failure | Metoprolol |
| BBW: beta adrenergic blocking agents - rapid withdrawal of oral forms may result in exacerbation of ________________. | Angina |
| Loop diuretic administered to patients with moderate to severe heart failure to reduce edema. | Furosemide |
Created by:
mcnabb
Popular Nursing sets